Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.57 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 2/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.43 |
| ▸ | ANPEP | P15144 | 2/20 | 0.41 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tyrosine SCHEMBL8981411 | 0.92 | SLC7A5 (0.71) | SLC7A5 | |
| SCHEMBL4453960 | 0.92 | SLC7A5 (0.67) | SLC7A5TAAR1HDAC8SLC6A2ESR1 | |
| SCHEMBL27680265 | 0.92 | SLC7A5 (0.67) | SLC7A5TAAR1HDAC8SLC6A2ESR1 | |
| SCHEMBL9521810 | 0.88 | SLC7A5 (0.54) | SLC7A5TAAR1HDAC8SLC6A2ESR1 | |
| Tyrosine SCHEMBL3796382 | 0.87 | SLC7A5 (0.63) | SLC7A5 | |
| SCHEMBL1422055 | 0.85 | SLC7A5 (0.64) | SLC7A5HDAC8 | |
| SCHEMBL27858204 | 0.85 | SLC7A5 (0.59) | SLC7A5TAAR1HDAC8SLC6A2ESR1 | |
| SCHEMBL9003809 | 0.85 | ALPI (0.58) | SLC7A5HDAC8ANPEP | |
| SCHEMBL27858201 | 0.85 | SLC7A5 (0.59) | SLC7A5TAAR1HDAC8SLC6A2ESR1 | |
| SCHEMBL28698332 | 0.85 | SLC7A5 (0.62) | SLC7A5TAAR1HDAC8SLC6A2ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240148040-A1 | METHODS OF REDUCING EXERCISE-INDUCED INJURY OR ENHANCING MUSCLE RECOVERY AFTER EXERCISE | TARGET CAPITAL 4 LLC | 2024-05-09 | — | — | US | claimed |
| WO-2022115353-A1 | METHODS OF REDUCING EXERCISE-INDUCED INJURY OR ENHANCING MUSCLE RECOVERY AFTER EXERCISE | INTRINSIC MEDICINE, INC. (US) | 2022-06-02 | — | — | WO | claimed |
| EP-3419615-A1 | DIETARY PRODUCT DEVOID OF AT LEAST TWO NON ESSENTIAL AMINO ACIDS | Cancer Research Technology Ltd. (GB) | 2019-01-02 | — | — | EP | claimed |
| WO-2017144877-A1 | DIETARY PRODUCT DEVOID OF AT LEAST TWO NON ESSENTIAL AMINO ACIDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-08-31 | — | — | WO | claimed |
| EP-1292615-B1 | MODIFIED MORBILLIVIRUS V PROTEINS | WYETH CORP (US) | 2006-10-25 | — | — | EP | claimed |
| US-6664066-B2 | Mutant measles virus V protein; gene expression and engineering | WYETH HOLDINGS CORPORATION | 2003-12-16 | — | — | US | claimed |
| US-20030206925-A1 | MODIFIED MORBILLIVIRUS V PROTEINS | WYETH HOLDINGS CORPORATION | 2003-11-06 | — | — | US | claimed |
| EP-4326284-A1 | INJECTABLE HYALURONIC ACID FORMULATIONS FOR USE IN INTRAARTICULAR, INTRADERMAL AND OPHTHALMIC APPLICATIONS | VSY Biyoteknoloji Ve Ilac Sanayi Anonim Sirketi (TR) | 2024-02-28 | — | — | EP | disclosed |
| US-20230399374-A1 | Compounds, Compositions and Methods of Use to Treat Bone Fractures | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-12-14 | — | — | US | disclosed |
| EP-4232074-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE TO TREAT BONE FRACTURES | Purdue Research Foundation (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-4218751-A2 | DIETARY PRODUCT DEVOID OF AT LEAST TWO NON ESSENTIAL AMINO ACID | Cancer Research Technology Ltd (GB) | 2023-08-02 | — | — | EP | disclosed |
| WO-2022093373-A1 | COMPOUNDS,COMPOSITIONS AND METHODS OF USE TO TREAT BONE FRACTURES | PURDUE RESEARCH FOUNDATION (US) | 2022-05-05 | — | — | WO | disclosed |
| US-20210283227-A1 | FRACTURE TARGETED BONE REGENERATION THROUGH PARATHYROID HORMONE RECEPTOR STIMULATION | PURDUE RESEARCH FOUNDATION | 2021-09-16 | — | — | US | disclosed |
| EP-0924193-A1 | Processes for producing optically active 2-amino-1-phenylethanol derivatives | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1999-06-23 | — | — | EP | disclosed |
| EP-0924194-A2 | Processes for producing optically active 2-amino-1-phenylethanol derivatives | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1999-06-23 | — | — | EP | disclosed |
| US-5811293-A | CULTURE PRODUCT AS CHEMICAL INTERMEDIATE FOR ANTI-OBESITY AGENT | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1998-09-22 | — | — | US | disclosed |
| US-5629200-A | MICROORGANISM | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1997-05-13 | — | — | US | disclosed |
| EP-0654534-A2 | Processes for producing optically active 2-amino-1-phenylethanol derivatives | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1995-05-24 | — | — | EP | disclosed |
| EP-0457701-B1 | Derivatives of endogenous mediators, their salts, process for preparation, application and compositions containing them | IMMUNOTECH SA (FR) | 1995-02-22 | — | — | EP | disclosed |
| EP-0457701-A1 | Derivatives of endogenous mediators, their salts, process for preparation, application and compositions containing them | IMMUNOTECH S.A. (FR) | 1991-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399374-A1 | Compounds, Compositions and Methods of Use to Treat Bone Fractures | SOST, BMP2, BMP4 | SLC7A5 3739/4885TAAR1 1799/4885HDAC8 2341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.